These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 19037667

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M.
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 5. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
    Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RM.
    Support Care Cancer; 2013 Oct; 21(10):2845-51. PubMed ID: 23748485
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM, Nagy CK, Gray SE.
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [Abstract] [Full Text] [Related]

  • 12. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L, Agustoni F, Testa I, Dotti K, de Braud F.
    Tumori; 2012 Jun; 98(3):279-86. PubMed ID: 22825501
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M, A El-Azab G, A Tawfik H.
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK, Wu CE, Liaw CC.
    Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
    [Abstract] [Full Text] [Related]

  • 17. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Enomoto T, Sato T, Kuranami M, Watanabe M.
    Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
    [Abstract] [Full Text] [Related]

  • 18. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T.
    Jpn J Clin Oncol; 2017 Sep 01; 47(9):840-843. PubMed ID: 28633504
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
    Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS.
    Support Care Cancer; 2013 Feb 01; 21(2):565-73. PubMed ID: 22869054
    [Abstract] [Full Text] [Related]

  • 20. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
    Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S.
    Ann Oncol; 2014 Jul 01; 25(7):1328-1333. PubMed ID: 24603643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.